Trial Profile
Phase I/II Study of Brentuximab Vedotin and Methotrexate/ L-asparaginase/ Dexamethasone (B-MAD) Chemotherapy in Patients With Newly-diagnosed Extranodal NK/ T-cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Asparaginase; Dexamethasone; Methotrexate
- Indications Extranodal NK-T-cell lymphoma
- Focus Adverse reactions
- 12 Dec 2023 Results(data cutoff date of June 30, 2023) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 24 Nov 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Dec 2023.
- 20 May 2023 Planned End Date changed from 31 Aug 2023 to 31 Dec 2023.